These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Bendamustine and G-CSF support. Imataki O; Uchida S; Yokokura S; Uemura M; Kadowaki N Support Care Cancer; 2019 May; 27(5):1581-1582. PubMed ID: 29484498 [No Abstract] [Full Text] [Related]
5. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab. Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012 [No Abstract] [Full Text] [Related]
6. Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature. Gomez A; Hoffman JE Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):e101-8. PubMed ID: 27245314 [No Abstract] [Full Text] [Related]
7. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. Yutaka T; Ito S; Ohigashi H; Naohiro M; Shimono J; Souichi S; Teshima T Leuk Lymphoma; 2015; 56(11):3216-8. PubMed ID: 25760636 [No Abstract] [Full Text] [Related]
8. Lichenoid drug eruption associated with Bendamustine. Kusano Y; Terui Y; Yokoyama M; Hatake K Blood Cancer J; 2016 Jun; 6(6):e438. PubMed ID: 27341077 [No Abstract] [Full Text] [Related]
9. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine. Shikdar S; Totton D; Turco T; Rachshtut M Anticancer Drugs; 2018 Sep; 29(8):814-816. PubMed ID: 29877929 [TBL] [Abstract][Full Text] [Related]
11. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805 [No Abstract] [Full Text] [Related]
12. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. Olszewski AJ; Reagan JL; Castillo JJ Am J Hematol; 2018 Jan; 93(1):E1-E3. PubMed ID: 28960532 [No Abstract] [Full Text] [Related]
13. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J; Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425 [TBL] [Abstract][Full Text] [Related]
14. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788 [No Abstract] [Full Text] [Related]
15. Fatal Cache Valley virus meningoencephalitis associated with rituximab maintenance therapy. Yang Y; Qiu J; Snyder-Keller A; Wu Y; Sun S; Sui H; Dean AB; Kramer L; Hernandez-Ilizaliturri F Am J Hematol; 2018 Aug; 93(4):590-594. PubMed ID: 29282755 [No Abstract] [Full Text] [Related]
16. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Gafter-Gvili A; Polliack A Leuk Lymphoma; 2016; 57(3):512-9. PubMed ID: 26696321 [TBL] [Abstract][Full Text] [Related]
17. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970 [No Abstract] [Full Text] [Related]
18. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859 [No Abstract] [Full Text] [Related]
19. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]